**Appendix Table D164. Decrease in frequency of migraine >50% with amitriptyline vs. placebo in adults with different baseline migraine frequency, results from medium risk of bias RCT111**

|  |  |  |  |
| --- | --- | --- | --- |
| **Baseline Migraine Frequency** | **Weeks of Treatment** | **Relative Risk** **(95% CI)** | **Absolute Risk Difference** **(95% CI)** |
| Baseline ≥17 Headaches per month | 4 | 5.5 (0.7 to 40.5) | **0.20 (0.04 to 0.37)** |
| Baseline 1-16 Headaches per month | 4 | 0.7 (0.3 to 1.5) | -0.04 (-0.10 to 0.03) |
| Baseline ≥17 Headaches per month | 8 | 1.7 (0.5 to 5.4) | 0.14 (-0.12 to 0.39) |
| Baseline 1-16 Headaches per month | 8 | 1.0 (0.5 to 2.2) | 0.00 (-0.08 to 0.08) |
| Baseline ≥17 Headaches per month | 12 | 5.0 (0.7 to 34.3) | **0.37 (0.11 to 0.63)** |
| Baseline 1-16 Headaches per month | 12 | 1.2 (0.6 to 2.5) | 0.02 (-0.08 to 0.12) |
| Baseline ≥17 Headaches per month | 16 | 1.8 (0.5 to 7.1) | 0.16 (-0.16 to 0.48) |
| Baseline 1-16 Headaches per month | 16 | 0.8 (0.4 to 1.8) | -0.03 (-0.13 to 0.07) |

Bold = significant difference at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval